Podium to Practice: Chicago 2025 – Melanoma: C-144-01 + AGNI-01

Podium to Practice: Chicago 2025 – Melanoma: C-144-01 + AGNI-01

Podium to Practice: Chicago 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Vanessa Bernstein

Icon Chair Speaker

Speakers

Dr. Omid Hamid

Dr. Elaine McWhirter

Studies / Trials Discussed

9515 – Lifileucel in patients with advanced melanoma: 5-year outcomes of the C-144-01 study.

9517 – OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients (pts) with immune checkpoint inhibitor (ICI)–resistant advanced melanoma: Phase 1 results of the Agni-01 multicenter study.

Studies/trials discussed:

9515 – Lifileucel in patients with advanced melanoma: 5-year outcomes of the C-144-01 study. 9517 – OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients (pts) with immune checkpoint inhibitor (ICI)–resistant advanced melanoma: Phase 1 results of the Agni-01 multicenter study.
Tagged